Skip to main content
Fig. 5 | BMC Endocrine Disorders

Fig. 5

From: Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

Fig. 5

Reductions in tumor volume for individual patients. Data are change-from-baseline to end of study (or early withdrawal) in the solid component of the tumor for patients in the intention-to-treat population. One patient (in the lanreotide autogel 120 mg group) was classed as an outlier and his/her data are not shown in this figure

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us